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Summary 
Successful antibody production in vivo depends on a number of cellular events, one of the most 
important of these being cognate B cell-T cell interaction. To examine this phenomenon in vitro, 
homogeneous populations of hen egg lysozyme (HEL)-specific small resting B cells and naive 
CD4 § HEL-specific T  cells (derived from immunoglobulin [Ig] and T  cell receptor transgenic 
mice, respectively) were cultured together. On addition of intact HEL protein,  HEL-specific 
B cells increase their expression of activation molecules, including a B7-related protein and CD44, 
and enlarge into blast cells. Within the same cultures, HEL-specific CD4 § T cells also increase 
expression of the activation markers CD69 and CD44, enlarge, secrete lymphokines, and proliferate. 
This response is radiation sensitive,  supporting the conclusion that HEL-specific B cells present 
antigen to and activate the naive T  cells.  By contrast, when a synthetic peptide fragment of 
HEL is used to bypass B cell antigen-receptor engagement, the naive T cells enlarge and display 
activation antigens, but fail to produce lymphokines, proliferate, or promote B cell blastogenesis. 
Presentation of HEL by tolerant B cells, which are no longer able to signal effectively through 
their antigen receptors, results in an identical pattern of incomplete T  cell activation. Addition 
of a stimulating anti-CD28  antibody and blocking of CD28  signals  with CTLA4/Ig fusion 
protein both  show  that  complete activation of naive CD4 §  T  cells  depends  on  the initial 
induction of B7 and related costimulatory molecules after HEL binding to nontolerant HEL- 
specific B cells.  Thus,  in the absence of adequate costimulation from the B cell,  naive CD4 § 
T  cells undergo a form of "partial activation" in which they upregulate surface expression of 
certain T cell activation antigens, but fail to efficiently produce lymphokine and proliferate. This 
may explain the different conclusions that have been reached regarding the consequences of B 
cell antigen presentation to T cells, in that the ability of B cells to activate naive CD4 § T cells 
depends both on their specificity and their activation state. 
F 
oreign antigens evoke an immune response by triggering 
an elaborate network of cell-cell interactions and activa- 
tion events. For effective antibody production, antigen-specific 
B cells must be activated to donally expand and differentiate 
into plasma cells, and this can depend on a variety of cells, 
including CD4 + helper T  cells (1), macrophages (2),  den- 
dritic cells (3-5), and follicular dendritic cells (6, 7). Many 
factors,  such as the form and amount of antigen, route of 
administration, the presence of particular adjuvants, and prior 
exposure to the antigen, influence whether a foreign antigen 
will elicit an antibody response, and to what extent partic- 
ular cell types are required. How each of these factors ulti- 
mately influences the immunogenicity or tolerogenicity of 
antigens is not well understood, in large part because of the 
many different cell interactions that may be affected. One 
of the key cellular interactions in antibody responses is that 
between antigen-specific B cells and cognate helper T  cells 
(1, 8,  9).  A  number of critical molecular events occurring 
during this interaction have been identified. First, helper T 
cell-dependent  antibody  production  depends  on  MHC- 
restricted recognition of antigen presented by the B cell. In 
response to T  cell recognition of presented antigens occur- 
ring through TCR, helper T cells can potentially display mol- 
ecules such as CD40L (10-13)  or membrane TNF  (14) on 
their cell surface,  or secrete the cytokines IL-2, IL-4, IL-5, 
or IL-10 (9). Each of these molecules has profound positive 
effects on B cell proliferation and differentiation into plasma 
cells.  Selective  delivery of T  cell help is  achieved because 
antigen-specifc B cells are much more efficient at taking up 
antigen for presentation to helper T cells, using their surface 
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for degradation into peptides that are then presented on the 
cell surface in association with class II MHC molecules (15). 
Presentation of antigen by B cells to helper T cells is neverthe- 
less not a simple inductive event leading inevitably to anti- 
body production, but may instead lead to tolerance or have 
no effect (1, 9, 16). Resolving what factors influence the out- 
come of this interaction is clearly important for understanding 
the immunogenicity or tolerogenicity of antigens, but has 
been limited by the need to use indirect in vivo assays or trans- 
formed or immortalized cell lines in vitro. 
To directly visualize interactions between antigen-specific 
B and T cells, we describe below the use of transgenic mice 
carrying rearranged Ig and TCR genes as a source of many 
homogeneous  resting  B  and  T  cells  specific  for  a  well- 
characterized protein antigen, hen egg lysozyme (HEL). Trans- 
genic mice were produced on an inbred C57BL/6 background 
carrying transgenes encoding the TCR oe and 13 chains from 
the HEL-specific T  cell hybridoma 3A9 (17, 18). Purified 
resting T cells from these mice were cultured in vitro with 
resting B cells from previously described transgenic mice ex- 
pressing heavy and light chain genes encoding high-afhnity 
HEL-specific IgM and IgD (19). On addition of HEL an- 
tigen, resting HEL-specific B cells could trigger a spectrum 
of responses in naive HEL-specific CD4 + T cells. The form 
taken by the resulting T  cell response is very much depen- 
dent on the activation state of the B cell and is determined 
at least in part by the induction of B7/B7-related  molecules 
on the B cells after B cell antigen-receptor engagement, and 
their subsequent interactions with CD28  on the T  cell. 
Materials and Methods 
Transgenic Mice.  Transgenic mice expressing HEL-specific  IgM 
and IgD and soluble HEL/anti-HEL "double-transgenic"  mice have 
been described elsewhere (19). Mice expressing the cytochrome 
C-specific TCR.-o~/~  5C.C7 have also been described (20-22). Mice 
expressing the HEL-specific  3A9 TCR were derived by inserting 
the 3A9 VJ~ and VDJ~ fragments into modified genomic shuttle 
vectors, the original forms of which have previously  been described 
(23). The B shuttle vector was modified such that it carried 7.5 
kb 3' to the constant region, including the TCR-B enhancer re- 
gion (24-26), instead  of  the Ig enhancer  originally  used  in the shuttle 
vector. The ol shuttle also had its Ig enhancer removed  and replaced 
with 3.5 kb 3' to the ce constant region (27). The VJ and VDJ 
regions of the cr  and ~/chains of the 3A9 TCR were amplified 
via PCR from cDNA clones (generously  provided by L. Glimcher, 
Harvard University, Cambridge, MA [18]) with oligo primers con- 
taining cDNA homology, splice  acceptor and donor sites, segments 
of intron  sequence, and restriction sites required for subcloning 
into the modified genomic shuttle vectors. Resulting VJ and VDJ 
cassettes were  gd purified, restricted,  and subcloned  into  the 
modified  shuttle vectors. Linearized  TCR-ce and -8 genomic shuttle 
constructs were then purified away  from vector sequences and coin- 
jected into fertilized C57BL/6J eggs. Two female founders were 
1Abbreviations used in this paper: HEL, hen egg lysozyme;  MCC, moth 
cytokine C; slg, surface Ig. 
generated. T cells  were obtained  from mice  derived  from one founder 
that had been crossed onto the B10.BR/SgSnJ background such 
that MHC class II A  k molecules were present during T cell de- 
velopment. C57BL/6J and B10.BR/SgSnJ inbred mice were ob- 
tained from The Jackson Laboratory (Bar Harbor, ME). 
Antiserum,  Antibodies, and Flow Cytometry.  Antiserum specific 
for the Voe chain of the 3A9 TCK was generated (Josman Labora- 
tories, Napa, CA) by immunizing a rabbit with chimeric protein 
consisting of the 3A9ce VJ region plus the IgG2a heavy chain con- 
stant region (28). Antiserum was preabsorbed on a mouse IgG 
column before use. Antibody to the murine TCK V/~/8.2 region 
was derived  from the hybridoma F23.2 (29) and biotinylated. Texas 
red-conjugated donkey anti-rabbit Ig was obtained from Jackson 
ImmunoResearch  (West Grove, PA) and avidin-allophycocyanin  from 
Biomeda (Foster City, CA). PE-conjugated anti-L3T4 and FITC- 
conjugated anti-Lyt2 were obtained from Becton Dickinson & Co. 
(San Jose, CA). Antibodies to murine Thyl.2, CDS, and rat IgG 
were obtained from CALTAG  Laboratories (South San Francisco, 
CA). Antibodies to murine CD43, I-E  k'r, CD44, and CD69 were 
obtained from Pharmingen (San Diego, CA). Avidin-FITC was 
obtained from Organon Teknika (West Chester, PA). The F4/80 
hybridoma was obtained from the American Type Culture Collec- 
tion (Rockville, MD). Anti-CD28  mAb was a generous gift of 
J. Allison (University of California at Berkeley). CTLA4/Ig fu- 
sion protein and control L6-Ig fusion protein were kindly provided 
by P. Linsley (Bristol-Meyers  Squibb, Pharmaceutical Research In- 
stitute, Seattle, WA). Staining with CTLA4/Ig was developed  with 
anti-human HTC (Tago Inc., Burlingame, CA). 
Purification of T and B  Cells.  Naive  CD4 + 3A9 T cells were 
derived based on the method of Sagerstr6m et al. (30). Inguinal, 
popliteal, axillary, brachial, cervical, mesenteric, and periaortic 
lymph nodes were harvested  from 3A9-transgenic  mice, and single- 
cell suspensions  were made by forcing the tissue through wire mesh. 
After washing in 5% FCS/RPMI 1640, cells were stained with 
anti-CD8-FITC,  anti-Ek-biotin (17.3.3), and anti-CD44-PE fol- 
lowed by avidin-FITC. Cell sorting was performed on a FACStar  | 
(Becton Dickinson & Co.), gating for FITCn~/CD44  l~ cells with 
additional forward and side scatter gates for small lymphocytes. 
The resulting population was >98% Thyl§  Naive CD4 § 5C.C7 
T cells were purified in the same way from 5C.C7-transgenic  mice. 
Small resting B cells were purified from anti-HEL Ig-transgenic 
or HEL/anti-HEL double-transgenic  mice by preparing splenocyte 
cell suspensions with wire mesh. Erythrocytes were removed by 
centrifugation over Lympholyte  |  medium (Accurate Chemical and 
Scientific Corp.,  Westbury, NY)  and lymphocytes washed and 
stained with anti-Thyl.2-FITC,  anti-CD43-FITC  (antibody  $7 [311), 
and a rat anti-routine macrophage (F4/80) mAb (32) followed  by 
anti-rat IgG-FITC. Cells were sorted as above, gating for FITC  ~n 
cells with additional forward and side scatter gates for small lym- 
phoeytes. The resulting population was >98%  B220  § 
Cell Culture.  T and B cells were cultured in RPMI 1640 medium 
supplemented with  10%  FCS, t-glutamine,  2-ME, and peni- 
cillin/streptomycin in 96-well flat-bottom polystyrene tissue cul- 
ture plates. Cultures contained 2  x  10  s sorted B cells and 1-1.5 
x  105 sorted T cells. To assay lymphokine production, cultures 
were incubated at 37~  in 5%  CO2 for 2 d, and supernatants 
were harvested and assayed  with the Ib2/IL-4-dependent cell line, 
HT-2 (33, 34). For phenotypic analyses,  cultured cells were stained 
with antibodies and analyzed via four-color flow cytometry, dead 
cells being gated out with propidium iodide. 
Proliferation Assay.  Sorted  B cells were irradiated using a Cs  137 
source. After culture with naive CD4 § cells and antigen for 2.5 d, 
wells were pulsed with 1 #Ci[3H]thymidine for 12 h, harvested, 
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beta counter (Packard Instruments,  Meriden,  CT). 
Antigens.  HEL was from Sigma Chemical Co. (St. Louis, MO). 
Moth cytochrome C (MCC) 88-103 peptide (ANERADLIAYLK- 
QATK) was synthesized and HEL peptide 46-61 (NTDGSTDYGIL- 
QINSR) was synthesized and HPLC-purified by the PAN facility 
of the Beckman Center for Molecular and Genetic Medicine (Stan- 
ford,  CA). 
Results 
Activation of Antigen-Specific  B and T  Cells.  As described 
in Materials and Methods, HEL-specific T cells were derived 
from TCK-transgenic  mice generated with a modified ver- 
sion of previously described (23) genomic TCR shuttle vectors 
(Fig.  1 A).  The vast majority of CD4 + lymphocytes from 
these transgenic mice expressed both chains of the 3A9 TCR, 
as evidenced by staining of lymph node cells with mAb specific 
for V/~8.2 and antiserum against the 3A9 oe chain (Fig.  1 B). 
Figure 1.  3A9 TCR transgenic mice. (A) Modified  TCK genomic  shuttle 
vectors. Shuttle vectors derived from the genomic TCR-a and TCR-B 
sequences of the hybridoma 2B4 were modified from the original (23), 
and 3A9 VJa and VDJ/~ sequences  inserted, as described  in Materials and 
Methods. (B) Expression of the 3A9 TCK on CD4 + lymphocytes.  Cells 
were derived from the lymph nodes of 3A9 TCR transgenic mice (H-2~) 
and nontransgenic littermates and stained with anti-L3T4 (PE), anti-Lyt2 
(FITC), biotinylated  F23.2 (anti-V/~8.2), avidin-allophycocyanin,  rabbit anti- 
3A9o~ antiserum, and anti-rabbit Ig (Texas red). Plots show levels  of ex- 
pression of the c~ and B chains on CD4 + cells  by use of 5% probability 
contour lines. 
To  examine  cognate  antigen  recognition  by both  small 
resting  B  cells  and  naive  CD4 §  T  cells,  purified  HEL- 
specific B and T cells were mixed and cultured either without 
antigen, with intact HEL, or with a synthetic HEL peptide 
(amino acids 46-61).  In the cultures containing intact HEL, 
the HEL-specific B cells exhibited a rapid increase in cell sur- 
face expression of B7 and related molecules detected by staining 
with CTLA4/Ig (35) and an increase in expression of CD44 
(36) (Fig.  2 A,  bottom, solid lines). By 48 h  of culture with 
HEL, expression of these markers had increased further, and 
the B cells were greatly enlarged, as indicated by the forward 
scatter (Fig.  2 B,  bottom, solid lines). None of these changes 
occurred in cultures of T  and B cells lacking HEL. Cultures 
of B cells with HEL but without T cells led to upregulation 
of CTLA4/Ig  staining  and CD44  expression  at  12 h,  but 
by 48 h  most of the B cells had died,  in contrast  to the B 
cell blastogenesis that occurred in the presence oft  cells (Fig. 
2,  A  and B,  top). 
In cultures oft and B cells containing HEL peptide (which 
does not bind to the HEL-specific Ig molecules expressed by 
the B cells),  a fraction of the B cells had increased the expres- 
sion of B7/B7-related and CD44 molecules, but none of the 
B cells formed large blast cells. This HEL peptide-induced 
B  cell  activation  is entirely T  cell dependent,  since  no in- 
crease  in CTLA4/Ig or CD44 staining occurred on B cells 
in peptide-stimulated  cultures lacking HEL-specific T  cells 
(Fig.  2,  A  and B,  broken lines). 
Parallel analysis  of T  cells in mixed B cell/T cell cultures 
showed that the presence of intact HEL induced the T  cells 
to express high levels of CD69 (37) by 12 h,  though there 
was no change in CD44 or in cell size  (Fig.  2 C,  top). By 
48 h,  all of the T  cells  had markedly elevated CD44 levels 
(38) and had enlarged into blasts (Fig.  2 C,  bottom). Addi- 
tion of HEL peptide instead of intact HEL also led to T cell 
activation, although induction of CD69, CD44, and cell en- 
largement  was somewhat  reduced (Fig.  2  C,  broken lines). 
Lymphokine Production by Naive CD4 + T  Cells.  Activa- 
tion of naive CD4 + T  cells in culture with antigen-specific 
B cells was further analyzed by measuring production of lym- 
phokines with the IL-2/IL-4-dependent cell line HT-2. HEL- 
specific T cells produced significant amounts of lymphokine 
in culture with  HEL-specific B cells  and intact  HEL (Fig. 
3 A,  open squares). A biphasic response was observed to in- 
creasing concentrations of added HEL. The first peak of lym- 
phokine production occurred at 10-nM HEL, which corre- 
sponds  to  the  Ka of the HEL-specific Ig expressed by the 
transgenic  B cells (39). By contrast,  much less lymphokine 
was produced by HEL-specific T  cells cultured with sorted 
B cells from nontransgenic  mice (which do not carry HEL- 
specific  Ig molecules), and this low-level response required 
103-10S-fold higher concentrations of HEL (solid squares). As 
further controls, naive CD4 + T  cells were sorted from non- 
transgenic  littermates  of the TClk-transgenic  mice.  When 
cultured with HEL and HEL-specific B cells, no detectable 
levels  of lymphokine  were produced  (data  not  shown).  In 
addition,  sorted TCR-transgenic T cells incubated with the 
HEL antigen,  but without added B cells,  demonstrated no 
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Figure 2.  Activation  of HEL-specific  B and T cells cultured with intact 
HEL or HEL peptide. Sorted small resting HEL-specific  B cells from (B6 
x B10.BR)Fl-transgenic  mice were cultured alone or mixed with sorted 
naive HEL-specific  CD4 § T cells from TCR-transgenic mice. The cells 
were cultured in media alone, 1/.tM HEL, or 1 #M HEL peptide (amino 
acids 46-61). At the indicated times of culture, cells were harvested, stained, 
and analyzed by flow cytometry. (A) Analysis of B220  + cells at 12 and 
(B) 48 h of culture, showing forward scatter as a measure of cell size and 
immunofluorescent staining with CTLA4/Ig or a monoclonal antibody 
to CD44. (C) CD4 § cells from the same cultures, showing cell size and 
immunofluorescent staining for CD69 or CD44. Note that histograms 
of HEL-exposed  B cells cultured alone for 48 h are derived from very few 
cells, since most of the cells had died as a result of this treatment. 
activation or lymphokine production (data not shown),  in- 
dicating that  the sorted T  cell population had no intrinsic 
APC  activity. 
To address whether other APCs such as macrophages or 
dendritic cells might contaminate the sorted B cell popula- 
tion and account for the activation of the transgenic T  cells, 
the HEL-specific B cells were irradiated before culture. Previous 
studies have established that APC activity of B cells is more 
radiosensitive than that of macrophages or dendritic cells (40, 
41). As shown in Fig. 3 B, naive T cells proliferated efficiently 
in cultures with intact HEL and HEL-specific B cells pretreated 
with  1,000  rad,  a  dose  that  leaves the  APC  activity of B 
cells relatively intact while preventing them from dividing. 
[3H]Thymidine  incorporation  by  T  cells  was  reduced  to 
background, however, when the B cells were pretreated with 
3,000 rad, a dose that has been shown to abolish B cell APC 
activity but spare APC activity in macrophages and dendritic 
cells (40, 41). This finding indicates that the B cells are respon- 
sible for activating naive CD4 + T  cells in  these cultures￿9 
Anti-CD28 Antibody Mimics the Effect of  Intact HEL on HEL- 
specific B CellAPC Function￿9  In contrast to the lymphokine 
production  stimulated  by intact  HEL protein,  little or no 
lyrnphokine was produced by cultures receiving the HEL pep- 
tide (Fig. 4, solid triangles). The possibility that the synthetic 
peptide was not taken up and presented by resting HEL-specific 
B cells was excluded, since induction of CD69,  CD44,  and 
blastogenesis occurred in the cultures receiving HEL peptide 
(Fig. 2 C). An alternative explanation for the failure to trigger 
lymphokine  production  was  that  the  B  cells lacked some 
costimulatory molecule that was induced when intact HEL 
bound to slg (42). Cultures of HEL-specific CD4 + T  cells 
and B cells were therefore stimulated with HEL peptide in 
the presence of anti-CD28 mAb (43) that would cross-link 
CD28 molecules on T cells and deliver a costimulatory signal 
(44-50). Lymphokine production by the T  cells was indeed 
restored by this treatment (Fig. 4, open triangles), confirming 
that  HEL peptide  loading of I-A  k had  occurred on the B 
cells and implying that  a costimulatory signal was lacking 
from the peptide-loaded-HEL-specific B  cells. 
Although  the above finding confirms that  HEL peptide 
is being presented by peptide-pulsed HEL-specific B cells, the 
difference between stimulation with intact HEL and HEL 
peptide might still reflect some quantitative differences in the 
amount of HEL peptide being presented￿9 To dissociate HEL 
binding from antigen presentation, naive CD4 § T  cells were 
purified from mice transgenic for a different TCR,  5C.C7 
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Figure 4.  Absence of lymphokine production by HEL-specific naive 
CD4 + cells cultured with  HEL-specific B  cells and  HEL peptide and 
rescue with CD28 costimulation.  HEL-specific T  and B cells were cul- 
tured as in Fig. 3 A and lymphokine production measured after 48 h ex- 
posure to intact HEL, HEL peptide (46-61), or HEL peptide plus mono- 
clonal antibody  to CD28. 
that intact HEL, like nonmitogenic antiolg antibodies, acti- 
vates a tyrosine kinase signaling pathway via surface Ig in 
HEL-specific Ig-transgenic B cells, and triggers rapid cell sur- 
face expression of B7 and related molecules as detected by 
the CTLA4/Ig fusion protein (51). CTLA4/Ig binds to B7 
and related molecules, and to test whether these were critical 
for lymphokine production, CTLA4/Ig was added to the 
Figure 3.  Response of naive HEL-specific CD4 + T cells to B cells and 
intact  HEL. (.4) Naive CD4 § T cells sorted from lymph nodes of 3A9 
TCR-transgenic mice were mixed with resting B cells sorted from spleens 
of anti-HEL Ig-transgenic  mice (or nontransgenic  littermates)  and cul- 
tured for 48 h with varying amounts of intact HEL. Culture supernatants 
were assayed for lymphokines by measuring proliferation  of HT-2, an IIr 
2/IL-4-dependent cell line. (B) Proliferative response in cultures of HEL- 
specific T and B cells measured by pH]thymidine  incorporation after 2.5-d 
culture  with 100, 10, or 0 nM HEL. Before culture,  the HEL-specific B 
cells were pretreated with either 1,000 or 3,000 tad irradiation. Horizontal 
line marks approximate upper boundary of background  counts obtained. 
(21, 22), which is specific for the MCC peptide 88-103 bound 
to  the  I-E  k  molecule  (20).  Increasing  concentrations  of 
MCC peptide were added to cultures of naive 5C.C7 T cells 
and HEL-specific B cells, and lymphokine production was 
assayed as before. Again, the small resting B cells exposed 
to peptide induced only very modest lymphokine produc- 
tion by the CD4 + T cells (Fig. 5, solid triangles). In contrast, 
addition of intact HEL to the cultures led to efficient lym- 
phokine production by the cytochrome-reactive T cells (open 
triangles). Somewhat higher stimulation could also be achieved 
by addition of anti-CD28  antibody (open circles). 
CTLA4/Ig Blocking Studies.  It has been shown previously 
m 
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Figure 5.  Presence of intact HEL or anti-CD28 antibody triggers lym- 
phokine production  by moth cytochrome C (MCC)-specific naive CD4 + 
T cells cultured with sorted HEL-specific  B cells and MCC peptide. MCC- 
specific naive CD4 + T cells were sorted from 5C.C7 TCR-transgenic  mice 
and cultured with HEL-specific B cells sorted  from Ig-transgenic  mice. 
The indicated concentrations  of MCC peptide  88-103 were added to the 
cultures  together with 10 nM HEL, anti-CD28 mAb, or no additional 
stimulus. Lymphokines were assayed from culture supernatants  after 48 h. 
1543  Ho et al. A 
.g 
￿9  +  1.6/lg control 
[]  + CTLA4/I g 
I  uM 
HEL 
10  nM 
B 
12h 
48h 
T  Cell  Activation 
~  nil 
￿9  .  --  HEL,+  ￿9 
[  L6/Ig 
---  HEI.+ 
'  CTI,A4/Ig 
J  & 
Forward  Scatter  CD69 
A 
CD44 
C 
12h 
48h 
B  Cell  Activation 
f 
Forward  Scatter  CTLA4/Ig  CD44 
Figure 6.  CTLA4/Ig  blocks lymphokine production by HEL-specific 
CD4 + T cells cultured with HEL-specific  B cells and intact HEL. HEL- 
specific T and B cells were cultured as in Fig. 3 A, except that either 10 
#g/ml CTLA4/Ig fusion protein or 10 #g/ml L6/Ig control fusion pro- 
tein (45) was added to the cultures. (A) Lymphokine  production. (B) In- 
duction of changes in cell size, CD69, and CD44 on CD4 § T cells. (C) 
Induction of  changes in cell size, CTLA4/Ig staining, and CD44 on B cells. 
cultures to block the binding  of B7 and related molecules 
to CD28 on the T cells (35). As shown in Figure 6 A, addi- 
tion of CTLA4/Ig abolished lymphokine production to back- 
ground levels. Control cultures receiving an irrelevant fusion 
protein, L6/Ig (45), produced large amounts of lymphokine. 
In contrast  to the striking  effect of CTLA4/Ig on lym- 
phokine  production,  the induction  of CD69,  CD44,  and 
blastogenesis is not abolished by this treatment  (Fig.  6 B). 
Although the degree of T cell enlargement and levels of cell 
surface markers were somewhat reduced, these observations 
were consistent with the response observed in T/B cell cul- 
tures stimulated with HEL peptide (Fig. 2 C). (Unlike peptide- 
stimulated cultures, however, HEL-binding B cells stimulated 
with intact  HEL but containing  CTLA4/Ig  continued  to 
undergo blastogenesis [Fig. 6 C]). These data show that the 
lack of a costimulatory signal through CD28 (and possibly 
CTLA4) leads to a state of "partial activation" in which T 
cells appear to be phenotypically activated but are profoundly 
deficient  in  lymphokine  production  and  subsequent  pro- 
liferation. 
Activation of Naive CD4 + T  Cells by Anergic B  Cells.  It 
has previously been found that HEL-specific B cells developing 
in "double-transgenic"  mice that express HEL as a soluble 
self-antigen are rendered anergic because of a proximal block 
in the slg-signaling pathway that prevents induction of B7 
and related molecules after antigen binding (51). To examine 
further the relationship between slg signaling, B cell activa- 
tion, and T cell activation, anergic small resting B cells derived 
from double-transgenic mice were cultured with HEL-specific 
T cells. In contrast to nontolerant B cells from Ig-transgenic 
mice, anergic B cells stimulated with intact HEL remained 
unable to trigger efficient lymphokine production by naive 
HEL-specific T cells (Fig. 7 A, open circles). As with the HEL 
peptide, addition of the anti-CD28 antibody restores T cell 
stimulation (solid circles), consistent with the notion that the 
tolerant B cells are capable of presenting antigen but simply 
lack expression of the necessary costimulatory molecules. Anal- 
ysis of these T cells cultured with tolerant double-transgenic 
B cells also shows that they are phenotypically activated even 
when HEL is not added to the cultures, implying that  the 
tolerant B cells had already been loaded with HEL peptide 
during continuous exposure in vivo (Fig. 7 B, thin lines). Ad- 
dition of exogenous HEL to the mixture of tolerant B cells 
and T cells triggered further induction of CD69 and CD44 
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Figure 7.  T cell  activation  by tolerant HELspecific  B cells  from HEL/anti- 
HEL double-transgenic mice. (.4) Lymphokine  production by naive CD4 + 
HEbspecific  T cells cultured for 2 d with either sorted nontolerant B cells 
from Ig-transgenic mice or tolerant B cells from HEL/anti-HEL double- 
transgenic mice. Anti-CD28 antibody was also added where indicated to 
provide exogenous costimulation. (B) Induction of changes in cell size, 
CD69, and CD44 in CD4 + HELspecific  T cells after 12 or 48 h culture 
with tolerant double-transgenic  B cells or nontolerant Ig-transgenic B cells, 
in the presence or absence of 10-/~M intact HEL. 
in the T cell population, but not to the same levels achieved 
in cultures with nontolerant HEL-specific B cells. Both tolerant 
and normal B cells were equally able to stimulate T  cell en- 
largement  (Fig.  7 B,  left,  12 versus 48 h). 
Discussion 
The findings discussed above demonstrate that antigen-spe- 
cific B cells can trigger cognate T cells to become activated, 
secrete lymphokine,  and proliferate.  This ability to activate 
T  cell effector functions is not constitutive, but depends on 
the specificity and activation state of the B cells. This varying 
competence of B cells to trigger different T cell effector func- 
tions  may play an  important  role in  determining  the im- 
munogenicity or tolerogenicity of antigens and may account 
for the contradictory findings in other  studies  (52-63). 
Naive CD4 + HEL-specific T  cells display a spectrum of 
cellular responses when cocultured with nontolerant  HEL- 
specific B cells and intact HEL antigen.  This spectrum in- 
cludes a marked increase in cell surface expression of CD69 
and CD44, T  cell enlargement into blast cells, lymphokine 
production, and T cell proliferation.  In addition, T cell-de- 
pendent blastogenesis is also triggered in the cocultured B 
cells (Fig. 2 B), presumably in response to T cell-derived lym- 
phokines or cell-bound signals  such as CD40L (10,  11, 13) 
or membrane TNF (14).  In contrast,  only parts of this re- 
sponse spectrum  are triggered  in  T  cells  when  antigen  is 
presented by HEL-specific B cells under conditions that pre- 
clude B cell activation via direct binding of intact HEL. Thus 
B cells exposed to the HEL peptide (which cannot engage 
the HEL-specific receptors on the B cells) trigger T cell en- 
largement and expression of CD69 and CD44, but no lym- 
phokine production occurs and no blastogenesis is induced 
in the B cells.  A  similar outcome was observed for CD4 § 
T  cells in mixtures  of T  cells and tolerant  HEL-specific B 
cells exposed to intact HEL. Rapid induction of CD69 on 
the cocultured T cells nevertheless confirms that the tolerant 
B cells are presenting intact HEL to T  cells effectively,  and 
that the B cells have in fact been loaded with HEL peptides 
during their prolonged exposure to HEL in vivo. Since tolerant 
B cells  are unable to sustain slg-mediated  signaling  and B 
cell activation after binding of intact HEL (51), their failure 
to trigger T  cell lymphokine production also points to the 
importance  of slg-mediated B cell activation. 
We also show here that costimulation through the CD28 
molecule can account,  at least in part,  for the stimulatory 
competence conferred on HEL-specific B cells by binding of 
intact antigen and subsequent slg signaling.  Binding of HEL 
to nontolerant HEL-specific B cells triggers rapid induction 
of cell surface molecules detected by CTLA4/Ig. These B7- 
related molecules detected on HEL-activated B cells are likely 
to be B7-2/B70 (64-67),  since they do not bind previously 
described B7-specific monoclonal antibodies,  nor can their 
staining with CTLA4/Ig be blocked by these monoclonal 
antibodies (Lenschow, D., J. Bluestone, M. P.  Cooke, and 
C. C. Goodnow, unpublished observations). B7 and related 
molecules were shown to be essential for induction of lym- 
phokine production by the T cells, since the latter was abol- 
ished in cultures where the B7 and related molecules were 
blocked by soluble CTLA4/Ig  (Fig.  6 A). 
Several lines of evidence suggest that the induction of B7 
and related molecules on B cells is not the sole determining 
factor rendering them competent to trigger the full spectrum 
of T cell responses.  First, CTLA4/Ig-reactive molecules were 
rapidly induced to equivalent levels on a reasonable fraction 
of HEL-specific B cells cultured with T  cells and the HEL 
peptide (Fig. 2 A, bottom center). Based on the studies of Nabavi 
et al. (68), it seems likely that the induction of these mole- 
cules occurs by signaling through  I-A  k molecules on the B 
cells that have been engaged by HEL/I-Ak-specific antigen 
receptors on the T  cells.  Since no lymphokine  production 
1545  Ho et al. or B cell blastogenesis resulted from these interactions, some 
additional event that occurs after binding of intact HEL must 
have been lacking in the peptide-stimulated cultures. 
The second piece of evidence pointing to an additional 
costimulatory pathway induced after HEL binding to B cells 
is the fact that B cell blastogenesis continued to occur in cul- 
tures with intact HEL when B7 and related molecules were 
blocked by CTLA4/Ig (Fig. 6 C, bottom left). Since blasto- 
genesis did not occur in B cells unless they were exposed to 
intact HEL and HEL-specific T cells, and T cell lymphokine 
production was blocked in CTLA4/Ig-treated cultures, other 
T cell effectors such as membrane-bound CD40L (10-13) or 
TNF (14) are presumably mediating this effect. Taken together 
with the lack of B cell blastogenesis in peptide-stimulated 
cultures, that which we see occurring in the CTLA4/Ig-treated 
cultures may depend on another molecule induced in HEL- 
exposed B cells that costimulates certain T cell effector func- 
tions. It will be important in future studies to identify the 
T  cell molecules responsible for B cell blastogenesis in cul- 
tures where B7 and related molecules are blocked and deter- 
mine if the additional costimulatory pathway involves known 
candidates such as IL-1, intercellular adhesion molecule 1, 
or heat-stable antigen (69-71). 
The role of B cells during a response to antigen has long 
been an  area of extensive investigation,  leading  to  many 
significant-but seemingly contradictory-conclusions (1, 41). 
For example, experiments with B cell-depleted mice have in- 
dicated that B cells play a vital role in the priming of T cells 
(52-57),  whereas work in a scid mouse transfer system has 
shown that B cells are not required for T cell priming (58). 
Within the question of whether antigen presentation by B 
cells is required for the activation of naive T cells is the point 
of whether B cells are even capable of activating naive T cells. 
A number of experimental approaches in chickens and mice 
have concluded that naive T  cells cannot be activated by B 
cells. Non-B APCs were needed to fully reconstitute an anti- 
body response in work by Lassila et al. (59), whereas Ron- 
chese and Hausmann (60) were unable to prime class II-re- 
stricted T cell responses by B cell antigen presentation, even 
when antigen-specific activated B cells were present. It has 
also been suggested that B cell antigen presentation can be 
tolerogenic (61, 62). Both studies looking at CTL responses 
in female mice immunized with either male B ceils or spleno- 
cytes (61) and work involving mice immunized with anti- 
IgD Fab fragments (62) demonstrated tolerance induced by 
B cell antigen presentation. Collectively, the findings of the 
highly simplified system presented here emphasize a remark- 
able degree of molecular coordination regulating the outcome 
of interactions between naive helper T  cells  and antigen- 
presenting B ceils. In our system, antigen-specific B ceils can 
indeed fully activate naive CD4 + T cells to upregulate acti- 
vation molecules, secrete lymphokine, and proliferate, but only 
if the B ceils have themselves been activated (by antigen) to 
provide crucial costimuli. These findings are consistent with 
the work of Croft et al. (63), which compared the relative 
capabilities  of different types of APCs to present antigen to 
and activate transgenic naive CD4 + T  cells.  Whether the 
"partial activation" of T  cells demonstrated here might be 
related to T cell tolerance or anergy-as the work of others 
(72-80) suggests-remains an intriguing possibility, although 
recent experiments by St. Louis et al. (81) have demonstrated 
the "partial activation" of T cell clones by a "costimulator- 
deficient" endothelial cell line, without any apparent induc- 
tion of T  cell anergy (81). 
From a broader perspective, the ability of B ceils to stimu- 
late particular T  cell effector functions may play a decisive 
role in determining the immunogenicity or tolerogenicity 
of antigens. For example, small amounts of soluble foreign 
antigens administered intravenously to primed individuals are 
generally found to be potent immunogens in the absence of 
any accompanying adjuvant.  In this case, immunogenicity 
may be ensured at least in part by efficient and selective up- 
take of antigen by antigen-specific memory B cells, which 
then become activated and competent to trigger helper T 
cells. In contrast, large amounts of soluble foreign antigen 
given intravenously to unprimed recipients are often tolero- 
genic (82).  Under these conditions,  antigen may be taken 
up and presented by many nonspecific resting B cells, which 
are unable to trigger the full spectrum of T cell effector func- 
tions, and may instead lead to T cell unresponsiveness. Fur- 
ther definition of the factors influencing the outcome of in- 
teractions between B cells,  T  cells,  and other cells in the 
lymphoid microenvironment should ultimately lead to a ra- 
tional basis for predicting the outcome of antigenic challenge. 
We thank James Allison for the anti-CD28 mAb, Peter Linsley for the gift of CTLA4/Ig and L6/Ig 
fusion proteins, and the Stanford Transgenic Facility and Nelida Prado for excellent technical assistance. 
W. Y. Ho was supported by the Medical Scientist Training Program grant 2T32GM07365 funded by 
the National Institute of General Medical Sciences. Experimental support was provided by the National 
Institutes  of Health  (AI-19512) and the Howard Hughes Medical Institute. 
Address correspondence to Dr. Mark M. Davis, Howard Hughes Medical Institute, Stanford University 
School of Medicine, Stanford, CA 94305-5428. M. P. Cooke is currently at Systemix Inc., New Enterprise 
Research Division, 3400 West Bayshore, Palo Alto, CA 94306. 
Received  for publication 24 November 1993 and in revised  form 4 February 1994. 
1546  Partial  Activation of Naive CD4  § T Cells by B Cells References 
1.  Finkelman, F.D., A. Lees, and S.C. Morris.  1992. Antigen pre- 
sentation by B lymphocytes to CD4 + T lymphocytes in vivo: 
importance for B lymphocyte and T  lymphocyte activation. 
Semin.  Immunol.  4:247. 
2.  Unanue, E.K., and P.M. Allen. 1987. The basis for the im- 
munoregulatory role of macrophages and other accessory cells. 
Science (Wash. DC).  236:551. 
3.  Inaba,  K., and K.M. Steinman. 1984. Resting and sensitized 
T lymphocytes exhibit distinct stimulatory (antigen-presenting 
cell) requirements for growth and lymphokine release.J. Exp. 
Med.  160:1717. 
4.  Inaba,  K., and K.M. Steinman. 1985. Protein-specific  helper 
T  lymphocyte formation initiated by dendritic cells. Science 
(Wash. DC).  229:475. 
5.  Inaba,  K., J.P.  Metlay,  M.T. Crowley, and K.M.  Steinman. 
1990. Dendritic cells pulsed with protein antigens in vitro can 
prime antigen-specific,  MHC-restricted T cells in situ.J. Exp. 
Med.  172:631. 
6.  Schriever, F., and L. M. Nadler.  1992. The central role of fol- 
licular dendritic cells in lymphoid tissues. Adv. Immunol. 51:243. 
7.  Tew, J.G., M.H. Kosco, G.F. Burton, and A.K. Szakal. 1990. 
Follicular dendritic cells as accessory cells. Immunol. Rev. 117:185. 
8.  Mitchison, N.A. 1971. The carrier effect in the secondary re- 
sponse to hapten-protein conjugates. II. Cellular cooperation. 
Eur. J,  Immunol.  1:18. 
9.  Parker, D.C. 1993. T cell-dependent B cell activation. Annu. 
Rev. Immunol.  11:331. 
10.  Armitage, R.J., W.C. Fanslow, L. Strockbine, T.A. Sato, K.N. 
Clifford, B.M.  Macduff, D.M.  Anderson,  S.D.  Gimpel, T. 
Davis-Smith, C.K. Maliszewski, E.A. Clark, et al. 1992. Mo- 
lecular and biological characterization of a murine ligand for 
CD40. Nature (Lond.). 357:80. 
11.  Noelle, K.J., M. Roy, D.M. Shepherd, I. Stamenkovic, J.A. 
Ledbetter, and A. Aruffo. 1992. A 39-kDa protein on activated 
helper T cells binds CD40 and transduces  the signal for cog- 
nate activation of B cells. Pro~ Natl. Acad. Sci. USA. 89:6550. 
12.  Lederman, S., M.J. Yellin, A. Krichevsky, J. Belko, J.J. Lee, 
and L. Chess.  1992. Identification of a novel surface protein 
on activated CD4 + T cells that induces contact-dependent B 
cell differentiation (help). J. Ext~ Med.  175:1091. 
13.  Ranheim, E.A., and T.J. Kipps. 1993. Activated T cells induce 
expression of B7/BB1 on normal or leukemic B cells through 
a CD40-dependent signal, j. Exp.  Med.  177:925. 
14.  Aversa, G., J. Punnonen, andJ.E, de Vries. 1993. The 26-kD 
transmembrane form of tumor necrosis factor oe on activated 
CD4 + T cell clones provides a costimulatory signal for human 
B cell activation. J. Ext~  Med.  177:1575. 
15.  Lanzavecchia, A. 1985. Antigen-specific interaction between 
T  and B cells. Nature  (Lond.). 314:537. 
16.  Parker, D.C.  1990. How does the helper T  cell activate  the 
resting B cell when it recognizes antigen on the B-cell sur- 
face? Res. Immunol.  141:405. 
17.  Allen, P.M., and E.K. Unanue. 1984. Differential requirements 
for antigen processing by macrophages for lysozyme-specific 
T  cell hybridomas. J. Immunol.  132:1077. 
18. Johnson, N.A., F. Carland, P.M. Allen, and L.H. Glimcher. 
1989. T cell receptor gene segment usage in a panel of hen- 
egg white lysozyme specific I-Ak-restricted T helper hybrid- 
omas. J.  Immunol.  142:3298. 
19.  Goodnow, C.C.,J. Crosbie, S. fiflelstein, T.B. Lavoie, S.J. Smith- 
Gill, K.A.  Brink,  H.  Pritchard-Briscoe, J.S.  Wotherspoon, 
R.H. Loblay, K. Raphael, et al. 1988. Altered immunoglob- 
ulin expression and functional silencing of self-reactive B lym- 
phocytes in transgenic mice. Nature (Lond.). 334:676. 
20.  Fink, P.J., L.A. Matis, D.L. McElligott, M. Bookman, and 
S.M. Hedrick. 1986. Correlations between T-cell specificity and 
the structure of the antigen receptor. Nature (Lond.). 321:219. 
21.  Fazekas de St. Groth, B., P.A. Patten, W.Y. Ho, E.P.  Rock, 
and M.M. Davis.  1993. An analysis of T cell receptor-ligand 
interaction using a transgenic antigen model for T cell toler- 
ance and T  cell receptor mutagenesis. In Molecular Mecha- 
nisms of Immunological Self-Recognition. F.W. Alt and H.J. 
Vogel, editors. Harcourt Brace Jovanovich, San Diego, CA. 
123-127. 
22.  Seder, K.A., W.A. Paul, M.M. Davis,  and B. Fazekas de St. 
Groth. 1992.  The presence of interleukin 4 during in vitro 
priming determines the lymphokine-producing potential of 
CD4 § T  cells from T  cell receptor transgenic mice. J. Exp. 
Med.  176:1091. 
23.  Patten, P.A., E.P. Rock, T. Sonoda, B. Fazekas de St. Groth, 
J.L. Jorgensen, and M.M.  Davis.  1993.  Transfer of putative 
complementarity-determining region loops of T cell receptor 
V  domains confers toxin reactivity but not peptide/MHC 
specificity. J.  Immunol.  150:2281. 
24.  Krimpenfort, P., K. deJong, Y. Uematsu, Z. Dembic, S. Ryser, 
H. von Boehmer, H. Steinmetz, and A. Berns. 1988. Tran- 
scription of T cell receptor beta-chain genes is controlled by 
a downstream  regulatory element. EMBO  (Eur. Mol.  Biol. 
Organ.) J.  7:745. 
25.  McDougall, S., C.L. Peterson, and K. Calame.  1988. A tran- 
scriptional enhancer 3' of C32 in the T cell receptor 3 locus. 
Science (Wash. DC).  241:205. 
26.  Takeda, J., A. Cheng, F. Mauxion, C.A. Nelson, R.D. New- 
berry, W.C. Sha, R. Sen, and D.Y. Loh. 1990. Functional anal- 
ysis of the murine T-cell receptor beta enhancer and character- 
istics of its DNA-binding proteins. Mol.  Cell. Biol. 10:5027. 
27.  Winoto, A., and D. Baltimore. 1989. A novel, inducible and 
T  cell-specific enhancer located at the 3' end of the T  cell 
receptor alpha locus. EMBO (Eur. Mol. Biol. Organ.)J. 8:729. 
28.  Gascoigne, N.R.J., C.C. Goodnow, K.I. Dudzik, V.T. Oi, and 
M.M.  Davis.  1987.  Secretion of a chimeric T-cell receptor- 
immunoglobulin protein. Pro~ Natl. Acad. Sci. USA. 84:2936. 
29.  Kappler, J.W., U. Staerz, J. White, and PC. Marrack. 1988. 
Self-tolerance eliminates T cells specific for Mls-modified prod- 
ucts of the major histocompatibility complex. Nature (Lond.). 
332:35. 
30.  Sagerstr6m, C.G., E.M. Kerr, J.P.  Allison, and M.M. Davis. 
1993. Activation and differentiation requirements of primary 
T  cells in vitro Proa Natl. Acad. Sci. USA.  90:8987. 
31.  Hardy, R.R., C.E. Carmack, S.A. Shinton, J.D. Kemp, and 
K. Hayakawa. 1991. Resolution and characterization of pro-B 
and pre-B cell stages in normal mouse bone marrow. J. Exl~ 
Med.  173:1213. 
32.  Austyn, J.M., and S. Gordon. 1981. F4/80, a monoclonal an- 
tibody directed specifically against the mouse macrophage. Eur. 
J. Immunol.  11:805. 
33.  Wettstein, D.A., J.J. Boniface, P.A. Reay, H. Schild, and M.M. 
Davis. 1991. Expression of a dass II major histocompatibility 
complex (MHC) heterodimer in a lipid-linked form with en- 
hanced peptideAoluble MHC complex formation at low pH. 
j.  Ext~ Med.  174:219. 
34.  Watson,J. 1979. Continuous proliferation ofmurine antigen- 
1547  Ho et at. specific helper T lymphocytes in culture.J. Exp. Med. 150:1510. 
35.  Linsley, P.S., N. Brady, M. Urnes, L.S. Grosmaire, N.K. Damle, 
andJ.A. Ledbetter. 1991. CTLA-4 is a second receptor for the 
B cell activation antigen B7. J. Exp. Med. 174:561. 
36.  Camp, R.L., T.A. Kraus, M.L. Birkeland, and E. Pur~. 1991. 
High levels of CD44 expression distinguish virgin from antigen- 
primed B cells. J. Exp. Med. 173:763. 
37.  Yokoyama, W.M., F. Koning, P.J. Kehn, G.M.B. Pereira, G. 
Stingl, J.E. Coligan, and E.M. Shevach.  1988. Characteriza- 
tion of a cell surface-expressed disulfide-linked  dimer involved 
in murine T  cell activation. J. Immunol. 141:369. 
38.  Haynes, B.F., M.J. Telen, L.P. Hale, and S.M. Denning. 1989. 
CD44: a molecule involved in leukocyte adherence and T-cell 
activation. ImmunoL Today. 10:423. 
39.  Goodnow, C.C., J. Crosbie, H. Jorgensen, R.A. Brink, and 
A. Basten. 1989. Induction of self-tolerance in mature periph- 
eral B lymphocytes. Nature (Lond.). 342:385. 
40.  Ashwell, J.D., M.K. Jenkins, and R.H. Schwartz. 1988. Effect 
of gamma radiation on resting B lymphocytes. II. Functional 
characterization of the antigen-presentation defect.J. Immunol. 
141:2536. 
41.  Ashwell, J.D. 1988. Are B lymphocytes the principal antigen- 
presenting cells in vivo? J. lmmunol.  140:3697. 
42. Jenkins, M.K., E. Burrell, and J.D. Ashwell.  1990. Antigen 
presentation by resting B cells: effectiveness at inducing T cell 
proliferation is determined by costimulatory signals, not T cell 
receptor occupancy. J. lmmunol.  144:1585. 
43.  Harding, F.A., J.G. McArthur, J.A. Gross, D.H. Raulet, and 
J.P. Allison. 1992. CD28-mediated signalling co-stimulates mu- 
fine T cells and prevents induction of anergy in T-cell clones. 
Nature (Lond.). 356:607. 
44. Jenkins, M.K., P.S. Taylor, S.D. Norton, and K.B. Urdahl. 1991. 
CD28 delivers a costimulatory signal involved in antigen-specific 
IL-2 production by human T  cells, j. Imrnunol. 147:2461. 
45.  Linsley, P.S., W. Brady, L. Grosmaire, A. Aruffo, N.K. Damle, 
and J.A. Ledbetter. 1991. Binding of the B cell activation an- 
tigen B7 to CD28 costimulates T cell proliferation and inter- 
leukin 2 mRNA  accumulation. J. Exp. Med. 173:721. 
46.  Gimmi, C.D.,  G.J.  Freeman, J.G.  Gribben, K. Sugita, A.S. 
Freedman, C. Morimoto, and L.M. Nadler. 1991. B-cell sur- 
face antigen B7 provides a costimulatory signal  that induces 
T cells to proliferate and secrete interleukin 2. Proc. Natl. Acad. 
Sci. USA.  88:6575. 
47.  Freeman, G.J., G.S. Gray, C.D. Gimmi, D.B. Lombard, L.J. 
Zhou, M. White, J.D. Fingeroth, J.G. Gribben, and L.M. Na- 
dler. 1991. Structure, expression, and T cell costimulatory ac- 
tivity of the murine homologue of the human B lymphocyte 
activation antigen B7. J. Exit Med. 174:625. 
48.  Norton,  S.D.,  L.  Zuckerman,  K.R  Urdahl,  R.  Shefner, J. 
Miller,  and M.K. Jenkins.  1992. The CD28 ligand, B7, en- 
hances IL-2 production by providing a costimulatory signal to 
T  cells, j. Immunol. 149:1556. 
49. June, C.H., J.A. Ledbetter, P.S. Linsley, and C.B. Thompson. 
1990. Role of the CD28 receptor in T-cell activation. Imrnunol. 
Today. 11:211. 
50.  Linsley, P.S., and J.A. Ledbetter. 1993. The role of the CD28 
receptor during T  cell responses  to antigen. Annu. Rev. Im- 
munol. 11:191. 
51.  Cooke,  M.P.,  A.W.  Heath,  K.M.  Shokat,  Y.  Zeng,  F.D. 
Finkelman, P.S. Linsley, M. Howard, and C.C. Goodnow. 1994. 
Immunoglobulin signal transduction guides the specificity of 
B cell-T cell interactions and is blocked in tolerant self-reactive 
B cells. J. Exp. Med. 179:425. 
52.  Ron, Y., P. De Baetselier, J. Gordon, M. Feldman, and S. Segal. 
1981. Defective induction of antigen-reactive proliferating T 
cells in B cell-deprived  mice. Eur. J. Irnmunol. 11:964. 
53.  Kon, Y., P. De Baetselier, E. Tzehoval, J. Gordon, M. Feldman, 
and S.  Segal.  1983. Defective induction of antigen-reactive 
proliferating T cells in B cell-deprived mice. II. Anti-g treat- 
ment affects the initiation and recruitment of T cells. Eur. j. 
Immunol. 13:167. 
54.  HayGlass, K.T., J.J. Naides, C.E Scott, Jr., B. Benacerraf, and 
M.S. Sy. 1986. T cell development in B cell-deficient mice. IV. 
The role of B cells as antigen-presenting cells in vivo. J. Im- 
munol. 136:823. 
55.  Kon, Y., andJ. Sprent. 1987. T cell priming in vivo: a major 
role for B cells in presenting antigen to T cells in lymph nodes. 
J. Immunol. 138:2848. 
56. Janeway, C.A., Jr., J. Kon, and M.E. Katz. 1987. The B cell 
is the initiating antigen-presenting cell in peripheral lymph 
nodes. J. Immunol. 138:1051. 
57.  Kurt-Jones, E.A., D. Liano, K.A. HayGlass,  B. Benacerraf, 
M.-S. Sy, and A.K. Abbas. 1988. The role of antigen presenting 
B cells in T  cell priming in vivo: studies  of B cell deficient 
mice. J. Imrnunol. 140:3773. 
58.  Sunshine,  G.H., B.L. Jimmo, C. Ianelli,  and L. Jarvis.  1991. 
Strong priming of T cells adoptively transferred into scid  mice. 
J. Exp. Med. 174:1653. 
59.  Lassila, O., O. Vainio, and P. Matzinger.  1988. Can B cells 
turn on virgin T  cells? Nature (Lond.). 334:253. 
60.  Konchese, E, and B. Hausmann. 1993. B lymphocytes in vivo 
fail to prime naive T cells but can stimulate antigen-experienced 
T  lymphocytes. J. Exp. Med. 177:679. 
61.  Fuchs,  E.J., and P. Matzinger.  1992. B cells turn off virgin 
but not memory T  cells. Science (Wash. DC).  258:1156. 
62.  Eynon, E.E., and D.C. Parker. 1992. Small B cells as antigen- 
presenting cells in the induction of tolerance to soluble pro- 
tein antigens. J. Exit Med. 175:131. 
63.  Croft, M., D.D. Duncan, and S.L. Swain.  1992. Response of 
naive antigen-specific CD4 + T cells in vitro: characteristics and 
antigen-presenting cell requirements. J. Exp. Med. 176:1431. 
64.  Hathcock,  K.S.,  G.  Laszlo,  H.B.  Dickler, J.  Bradshaw,  E 
Linsley, and K. Hodes. 1993. Identification of an alternative 
CTLA-4 ligand costimulatory for T  cell activation. Science 
(Wash. DC). 262:905. 
65.  Freeman, G.J., E Borriello, R.J. Hodes, H. Reiser, K.S. Hath- 
cock, G. Laszlo, A.J. McKnight, J. Kim, L. Du, D.B. Lom- 
bard, et al. 1993. Uncovering of functional alternative CTLA-4 
counter-receptor in  B7-deficient  mice.  Science (Wash. DC). 
262:907. 
66.  Freeman, G.J., J.G. Gribben, V.A. Boussiotis, J.W. Ng, V.A. 
Restivo, Jr., L.A. Lombard, G.S. Gray, and L.M. Nadler. 1993. 
Cloning of B7-2:  a CTLA-4 counter-receptor that costimu- 
lates human T cell proliferation. Science (Wash. DC). 262:909. 
67.  Azuma, M., D. Ito, H. Yagita, K. Okumura, J.H. Phillips, 
L.L. Lanier, and C. Somoza. 1993. B70 antigen is a second 
ligand for CTLA-4 and CD28. Nature (Lond.). 366:76. 
68.  Nahavi, N., G.J. Freeman, A. Gault, D. Godfrey, L.M. Nadler, 
and L.H. Glimcher. 1992. Signalling  through the MHC class 
II cytoplasmic domain is required for antigen presentation and 
induces B7 expression.  Nature (Lond.). 360:266. 
69.  Damle, N.K., K. Klussman, P.S. Linsley, and A. Aruffo. 1992. 
Differential costimulatory effects of adhesion  molecules B7, 
ICAM-1, LFA-3, and VCAM-1 on resting and antigen-primed 
CD4 + T  lymphocytes. J. Immunol. 148:1985. 
70.  Liu, Y., B. Jones, A. Aruffo, K.M. Sullivan, P.S. Linsley, and 
1548  Partial  Activation of Naive CD4 § T Cells by B Cells C.A. Janeway, Jr. 1992. Heat-stable antigen is a costimulatory 
molecule for CD4 T  cell growth. J. Exp.  Med.  175:437. 
71.  Liu, Y., B. Jones, W. Brady, C.A. Janeway, Jr., and P.S. Linsley. 
1992. Costimulation of routine CD4 T cell growth: coopera- 
tion  between  B7  and  heat-stable antigen.  Eur. J,  Immunol. 
22:2855. 
72.  Sloan-Lancaster,  J., B.D.  Evavold,  and P.M.  Allen.  1993. In- 
duction of T-cell anergy by altered T-cell-receptor ligand on 
live antigen-presenting cells. Nature (Lond.). 363:156. 
73.  Gimmi, C.D., G.J. Freeman, J.G. Gribben, G. Gray, and L.M. 
Nadler.  1993.  Human T-ceU clonal anergy is induced by an- 
tigen presentation in the absence of B7 costimulation. Proc. 
Natl. Acad.  Sci. USA.  90:6586. 
74.  Jenkins, M.K., and R.H. Schwartz.  1987. Antigen presenta- 
tion by chemically modified splenocytes induces antigen-specific 
T  cell  unresponsiveness  in  vitro  and  in  vivo. J.  Exp.  Med. 
165:302. 
75.  Jenkins, M.K., D.M. Pardoll, J. Mizuguchi, T.T. Chused, and 
K.H. Schwartz.  1987.  Molecular events in the induction  of 
a  nonresponsive  state  in  interleukin  2-producing  helper 
T-lymphocyte clones. Proc. Natl. Acad. Sci. USA.  84:5409. 
76.  Jenkins, M.K., J.D. Ashwell, and K.H. Schwartz.  1988. A1- 
logeneic nonoT spleen cells restore the responsiveness of normal 
T cell clones stimulated with antigen and chemically modified 
antigen-presenting cells. J. Immunol.  140:3324. 
77.  Mueller, D.L., M.K. Jenkins, and R.H. Schwartz.  1989. Clonal 
expression versus functional clonal inactivation: a costimula- 
tory signalling pathway determines the outcome of T cell an- 
tigen receptor occupancy.  Annu.  Rev. Immunol.  7:445. 
78.  Schwartz, R.H., D.L. Mueller,  M.K. Jenkins, and H. Quill. 
1989.  T-cell clonal anergy. Cold Spring Harbor Symt~ Quant. 
Biol. 2:605. 
79.  Schwartz, R.H. 1990. A cell culture model for T lymphocyte 
clonal anergy. Science (Wash. DC).  248:1349. 
80.  Schwartz, R.H.  1992. Costimulation of T lymphocytes: the 
role of CD28, CTLA-4, and B7/BB1 in interleukin-2 produc- 
tion and immunotherapy. Ceil. 71:1065. 
81.  St.  Louis,  J.D.,  J.A.  Lederer,  and  A.H.  Lichtman.  1993. 
Costimulator deficient antigen presentation by an endothelial 
cell line induces a nonproliferative T cell activation response 
without  anergy. J. Exp.  Med. 178:1597. 
82.  Dresser, D.W.,  and N.A.  Mitchison.  1968. The mechanism 
of immunological paralysis.  Adv. Immunol.  8:129. 
1549  Ho et al. 